Cyber Swan Sale

50% Off Elite

Days

Hours

Mins

Sec

Get our most powerful screeners, new charting tools, and the fastest ad-free experience at our best price ever. One last chance.

RAPT

RAPT Therapeutics Inc

Dec 05 • 04:00PM ET

34.47

-0.01 -0.01 %

Healthcare • Biotechnology • USA • NASD

Peers: GILD INCY NBIX EXEL BPMC FGEN APLS KURA BLUE LITS

| Held by: VTI VXF DWAS PRFZ AVSC RFLR BTEC CHNA

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-11.07	Insider Own	35.50%	Shs Outstand	27.71M	Perf Week	1.97%
Market Cap	955.05M	Forward P/E	-	EPS next Y	-3.36	Insider Trans	0.00%	Shs Float	17.87M	Perf Month	21.91%
Enterprise Value	800.31M	PEG	-	EPS next Q	-0.75	Inst Own	30.07%	Short Float	6.10%	Perf Quarter	159.53%
Income	-105.64M	P/S	-	EPS this Y	90.64%	Inst Trans	-1.00%	Short Ratio	2.38	Perf Half Y	268.22%
Sales	0.00M	P/B	3.82	EPS next Y	-40.52%	ROA	-77.05%	Short Interest	1.09M	Perf YTD	172.67%
Book/sh	9.02	P/C	6.07	EPS next 5Y	45.47%	ROE	-85.37%	52W High	42.39 -18.70%	Perf Year	259.01%
Cash/sh	5.68	P/FCF	-	EPS past 3/5Y	-8.04% -10.10%	ROIC	-69.33%	52W Low	5.67 508.36%	Perf 3Y	-75.63%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.48% 6.52%	Perf 5Y	-80.12%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	50.23%	Oper. Margin	-	ATR (14)	2.18	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	12.04	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	66.39	Recom	1.30
Dividend Gr. 3/5Y	- -	Current Ratio	12.04	EPS Q/Q	82.80%	SMA20	14.12%	Beta	0.46	Target Price	64.38
Payout	-	Debt/Eq	0.02	Sales Q/Q	-	SMA50	17.00%	Rel Volume	0.79	Prev Close	34.47
Employees	68	LT Debt/Eq	0.00	Earnings	Nov 06 BMO	SMA200	132.49%	Avg Volume	458.67K	Price	34.47
IPO	Oct 31, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	33.54% -	Trades		Volume	362,952	Change	-0.01%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-27-25	Initiated	Guggenheim	Buy	$70
Oct-20-25	Upgrade	JP Morgan	Neutral → Overweight	$55
Oct-13-25	Initiated	Barclays	Overweight	$35
Sep-26-25	Upgrade	Leerink Partners	Market Perform → Outperform	$37
Jul-30-25	Upgrade	JP Morgan	Underweight → Neutral	$14
May-22-25	Resumed	H.C. Wainwright	Buy	$6
Dec-26-24	Upgrade	H.C. Wainwright	Neutral → Buy	$10
Nov-13-24	Downgrade	Stifel	Buy → Hold	$7 → $2
Nov-11-24	Downgrade	Piper Sandler	Overweight → Neutral	$8 → $2
Nov-11-24	Downgrade	JP Morgan	Neutral → Underweight
May-14-24	Downgrade	Wolfe Research	Outperform → Peer Perform
May-10-24	Downgrade	Guggenheim	Buy → Neutral
May-10-24	Downgrade	Barclays	Overweight → Equal Weight	$13 → $4
Feb-22-24	Downgrade	UBS	Buy → Neutral	$61 → $10
Feb-21-24	Downgrade	Leerink Partners	Outperform → Market Perform	$42 → $10
Feb-21-24	Downgrade	JP Morgan	Overweight → Neutral	$35 → $15
Feb-21-24	Downgrade	H.C. Wainwright	Buy → Neutral
Feb-20-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Feb-16-24	Initiated	Evercore ISI	Outperform
Feb-15-24	Initiated	Wolfe Research	Outperform	$39

Show Previous Ratings

Nov-06-25 08:00AM	RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights (GlobeNewswire)
Nov-04-25 04:05PM	RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences (GlobeNewswire)
Oct-27-25 08:00AM	RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies (GlobeNewswire)
Oct-26-25 06:06AM	Wells Fargo Boosts RAPT Therapeutics (RAPT) PT to $48 on Promising Anti-IgE Drug Data (Insider Monkey)
Oct-21-25 11:12PM	RAPT Therapeutics Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -10.53%
04:01PM	Loading…
04:01PM	RAPT Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Oct-20-25 04:11PM	Rapt Therapeutics, Outperforming 98% Of All Stocks, Rockets After Topping Roche (Investor's Business Daily) +14.76%
09:20AM	Rapt Therapeutics, Outperforming 98% Of All Stocks, Skyrockets After Topping Roche (Investor's Business Daily)
08:00AM	RAPT Therapeutics and Shanghai Jeyou Pharmaceutical Announce Positive Topline Data from Phase 2 Trial of RPT904 (JYB1904) in Chronic Spontaneous Urticaria (GlobeNewswire)
Oct-19-25 08:00AM	RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU) (GlobeNewswire)
Sep-29-25 05:00AM	RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy (GlobeNewswire)
Aug-27-25 08:00AM	RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences (GlobeNewswire)
Aug-18-25 09:55AM	Wall Street Analysts Think Rapt Therapeutics (RAPT) Could Surge 101.02%: Read This Before Placing a Bet (Zacks)
Aug-12-25 09:55AM	Rapt Therapeutics (RAPT)'s Technical Outlook is Bright After Key Golden Cross (Zacks) +14.14%
Aug-07-25 08:00AM	RAPT Therapeutics Reports Second Quarter 2025 Financial Results (GlobeNewswire)
09:55AM	Loading…
Aug-01-25 09:55AM	Wall Street Analysts Believe Rapt Therapeutics (RAPT) Could Rally 122.22%: Here's is How to Trade (Zacks)
Jul-15-25 12:00PM	Rapt Therapeutics (RAPT) Upgraded to Strong Buy: Here's Why (Zacks) +21.67%
10:00AM	Best Momentum Stocks to Buy for July 15th (Zacks)
09:55AM	Does Rapt Therapeutics (RAPT) Have the Potential to Rally 183.83% as Wall Street Analysts Expect? (Zacks)
05:54AM	New Strong Buy Stocks for July 15th (Zacks)
Jun-23-25 08:00AM	RAPT Therapeutics Names Two Industry Veterans to its Board of Directors (GlobeNewswire)
Jun-18-25 09:55AM	Wall Street Analysts Predict a 282.65% Upside in Rapt Therapeutics (RAPT): Here's What You Should Know (Zacks) -5.36%
Jun-14-25 09:05AM	Rapt Therapeutics announces effective date for 1-for-8 reverse stock split (TipRanks)
Jun-13-25 09:00AM	RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split (GlobeNewswire)
Jun-04-25 04:05PM	RAPT Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-16-25 12:00PM	Rapt Therapeutics (RAPT) Upgraded to Buy: Here's What You Should Know (Zacks)
May-08-25 08:00AM	RAPT Therapeutics Reports First Quarter 2025 Financial Results (GlobeNewswire)
Apr-15-25 08:00AM	RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development (GlobeNewswire) -7.41%
Mar-07-25 04:30PM	RAPT Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.31%
Mar-06-25 08:00AM	RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
06:29AM	Loading…
Feb-18-25 06:29AM	Hanmi Pharmaceuticals reports data from trial of Tivumecirnon for gastric cancer (Clinical Trials Arena)
Feb-10-25 12:00PM	All You Need to Know About Rapt Therapeutics (RAPT) Rating Upgrade to Buy (Zacks)
Jan-09-25 08:00AM	RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-06-25 08:00AM	RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors (GlobeNewswire)
Dec-27-24 06:10AM	Rapt Therapeutics upgraded to Buy from Neutral at H.C. Wainwright (TipRanks) -6.63%
Dec-26-24 09:35AM	Progressive, EverQuote upgraded: Wall Street's top analyst calls (The Fly)
Dec-24-24 06:44AM	RAPT Therapeutics and Shanghai Jemincare sign anti-IgE antibody agreement (Pharmaceutical Technology)
Dec-23-24 01:00PM	Why RAPT Therapeutics Stock Gained Over 100% On Monday? (Benzinga) +110.81%
07:10AM	RAPT Therapeutics Announces $150 Million Private Placement (GlobeNewswire)
07:00AM	RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody (GlobeNewswire)
Nov-12-24 08:00AM	RAPT Therapeutics Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-11-24 12:18PM	RAPT Therapeutics shares tumble by 48% after zelnecirnon programme cull (Clinical Trials Arena) -39.45%
08:00AM	Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury (GlobeNewswire)
Sep-29-24 07:57AM	RAPT Therapeutics, Inc. (RAPT): Worst 52-Week Low Stock to Buy Now (Insider Monkey)
Sep-25-24 11:34AM	RAPT Therapeutics, Inc. (RAPT) Stock Falls Following FDA Setback; Short Sellers Cite Unprofitability (Insider Monkey)
Aug-08-24 08:00AM	RAPT Therapeutics Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jun-21-24 01:13AM	Should You Sell Your Stake in RAPT Therapeutics (RAPT)? (Insider Monkey)
Jun-14-24 09:35AM	Down -15.94% in 4 Weeks, Here's Why Rapt Therapeutics (RAPT) Looks Ripe for a Turnaround (Zacks)
May-29-24 09:35AM	Rapt Therapeutics (RAPT) Loses -47.08% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
May-14-24 07:08AM	Wolfe Research Downgrades RAPT Therapeutics to Peer Perform From Outperform (MT Newswires) -9.09%
May-13-24 09:35AM	Here's Why Rapt Therapeutics (RAPT) is Poised for a Turnaround After Losing -52.88% in 4 Weeks (Zacks)
May-10-24 03:46PM	RAPT Therapeutics Inc. Reports Q1 2024 Earnings: A Detailed Financial Overview (GuruFocus.com) -7.08%
07:55AM	Guggenheim Downgrades RAPT Therapeutics to Neutral From Buy (MT Newswires)
07:54AM	Barclays Downgrades RAPT Therapeutics to Equalweight, Price Target at $4 (MT Newswires)
May-09-24 04:12PM	What's Going On With Dermatitis-Focused RAPT Therapeutics Stock On Thursday? (Benzinga) -41.60%
03:59PM	Sector Update: Health Care Stocks Higher Late Afternoon (MT Newswires)
02:31PM	RAPT Therapeutics Shares Plunge After Wider Q1 Loss, Closing of Zelnecirnon Trials (MT Newswires)
01:53PM	RAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	RAPT Therapeutics Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-09-24 12:00PM	RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients (GlobeNewswire)
06:31AM	3 Biotech Stocks to Dump Before They Go to Zero (InvestorPlace)
Mar-22-24 05:39AM	What Makes RAPT Therapeutics (RAPT) an Investment Choice? (Insider Monkey)
Mar-07-24 02:52PM	RAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q4 2023 (InvestorPlace)
08:36AM	Should You Buy RAPT Therapeutics (RAPT) Ahead of Earnings? (Zacks)
08:00AM	RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-05-24 04:30PM	RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) +5.30%
Feb-20-24 04:03PM	Rapt Therapeutics Crashes 74% After Unexpected Liver Failure Sidelines Two Tests (Investor's Business Daily) -73.55% +48.18%
11:22AM	RAPT Therapeutics Stock Is Down 63%. FDA Halts 2 Studies After Liver Failure. (Barrons.com)
07:58AM	UPDATE 1-FDA puts on hold two Rapt Therapeutics mid-stage drug trials (Reuters)
07:39AM	RAPT Therapeutics says FDA puts two mid-stage trials of company's drug on hold (Reuters)
07:30AM	RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon (GlobeNewswire)
07:17AM	FDA puts hold on Rapt trials of drug for eczema, asthma (BioPharma Dive)
Feb-13-24 08:00AM	RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations (GlobeNewswire) -5.52%
Jan-31-24 08:00AM	RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-02-24 08:00AM	RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-27-23 08:00AM	RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy (GlobeNewswire)
Nov-14-23 07:41PM	RAPT Therapeutics Inc Reports Increased R&D Expenses Amid Progress in Clinical Trials (GuruFocus.com) -5.28%
Nov-13-23 08:00AM	RAPT Therapeutics Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-03-23 12:00PM	RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC (GlobeNewswire) +9.08%
Nov-01-23 04:05PM	RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in November (GlobeNewswire) +8.21%
Oct-18-23 09:00AM	RAPT Therapeutics Announces Two FLX475 Presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting (GlobeNewswire)
Sep-27-23 09:24PM	7 Strong Buy Biotech Stocks to Rejuvenate Your Portfolio (InvestorPlace)
Sep-14-23 09:44AM	Etsy upgraded, RTX downgraded to Sell: Wall Street's top analyst calls (The Fly)
Aug-30-23 04:05PM	RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September (GlobeNewswire)
Aug-16-23 09:55AM	How Much Upside is Left in Rapt Therapeutics (RAPT)? Wall Street Analysts Think 90.48% (Zacks) -9.45%
Aug-11-23 08:00AM	RAPT Therapeutics Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-09-23 10:26AM	UPS downgraded, Eli Lilly upgraded: Wall Street's top analyst calls (The Fly) +6.51%
Aug-08-23 06:03AM	This RAPT Therapeutics Insider Increased Their Holding By 22% Last Year (Simply Wall St.)
Jun-07-23 08:00AM	RAPT Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference (GlobeNewswire)
May-25-23 05:00PM	RAPT Therapeutics to Present Biomarker Data Corroborating Demonstrated Clinical Activity and Mechanism of Action of FLX475 in Advanced Cancers (GlobeNewswire)
May-11-23 08:00AM	RAPT Therapeutics Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-03-23 08:00AM	RAPT Therapeutics Announces the Appointment of Michael Listgarten as General Counsel (GlobeNewswire) +6.89%
Apr-26-23 04:19PM	RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Mar-29-23 08:00AM	RAPT Therapeutics Announces Initiation of Phase 2a Trial of RPT193 in Patients with Moderate-to-Severe Asthma (GlobeNewswire)
Mar-21-23 08:50AM	Here's Why We're Not Too Worried About RAPT Therapeutics' (NASDAQ:RAPT) Cash Burn Situation (Simply Wall St.)
Mar-14-23 08:00AM	RAPT Therapeutics Reports Fourth Quarter And Year End Financial Results (GlobeNewswire) -25.97%
Mar-02-23 10:00AM	Rapt Therapeutics (RAPT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Feb-28-23 08:00AM	Factors to Note Ahead of Hewlett Packard (HPE) Q1 Earnings (Zacks)
Feb-27-23 09:55AM	Wall Street Analysts See a 57.57% Upside in Rapt Therapeutics (RAPT): Can the Stock Really Move This High? (Zacks)
Feb-23-23 08:50AM	What Makes Rapt Therapeutics (RAPT) a Good Fit for 'Trend Investing' (Zacks)

Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company was founded in 2015 and is headquartered in South San Francisco, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Cyber Swan Sale

50% Off Elite

RAPT

RAPT Therapeutics Inc

Upgrade your FINVIZ experience